INTRODUCTION {#s1}
============

Liver cancer is the second leading cause of cancer mortality worldwide, causing more than 700,000 deaths annually \[[@R1]\]. Liver transplantation (LT) is the best curative treatment modality, achieving up to 91% 1-year survival post-transplantation \[[@R2]\]. However, finding the right donor liver is rare, and the patient must live as long as possible to wait for the liver from an appropriate donor. Therefore, the sooner the disease is diagnosed, the better. A safer and more effective diagnostic method is desirable. Biomarkers represent a potentially alternative method for diagnosis.

Proteomic technologies have enabled the identification of novel protein biomarkers \[[@R3]\]. Isobaric tags for relative and absolute quantification (iTRAQ) is a technique developed by the Applied Biosystems Incorporation \[[@R4]\]. In the present study, iTRAQ was used to analyse the total protein content of serum from patients with LT. iTRAQ was combined with Gene Ontology (GO) and pathway analysis to identify proteins that are differentially expressed in LT and determine their predicted functions.

RESULTS {#s2}
=======

Protein identification {#s2_1}
----------------------

In this iTRAQ quantification project, there were 5 homogeneous samples named A, B, C, D, E, and we performed 1 technical duplicate experiment. In total, 401198 spectrums were generated, and 6173 peptides and 1399 proteins were identified with the following cutoff: Mascot Percolator \[[@R5]\] Q-value ≤ 0.01 (more details on the method page of the MS/MS Ion Search).

Protein quantification {#s2_2}
----------------------

These proteins, from the B-VS-A, were divided into 112 upregulated by ratio_B\_114/A_113\>1.2 (Table [1](#T1){ref-type="table"}). Twenty-two proteins were identified, which were divided by a ratio \>2.

###### The upregulated proteins in serum samples of liver transplantation (Part of the data)

  No.      Protein_ID                         Description                                                                                                                                 Ratio_B\_114/A_113
  -------- ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  **1**    tr\|J3QRK0\|J3QRK0_HUMAN           Integrin beta-4 (Fragment) OS=Homo sapiens GN=ITGB4 PE=1 SV=1                                                                               10
  **2**    tr\|B4DUI8\|B4DUI8_HUMAN           cDNA FLJ52761, highly similar to Actin, aortic smooth muscle OS=Homo sapiens PE=2 SV=1                                                      10
  **3**    sp\|Q3SY84\|K2C71_HUMAN            Keratin, type II cytoskeletal 71 OS=Homo sapiens GN=KRT71 PE=1 SV=3                                                                         10
  **4**    sp\|Q8IYL3\|CA174_HUMAN            UPF0688 protein C1orf174 OS=Homo sapiens GN=C1orf174 PE=1 SV=2                                                                              10
  **5**    tr\|J3KSQ2\|J3KSQ2_HUMAN           Clathrin heavy chain 1 (Fragment) OS=Homo sapiens GN=CLTC PE=1 SV=1                                                                         9.594
  **6**    tr\|A8K6A5\|A8K6A5_HUMAN           cDNA FLJ77742, highly similar to Homo sapiens integrin, alpha 5 (fibronectin receptor, alpha polypeptide), mRNA OS=Homo sapiens PE=2 SV=1   9.575
  **7**    tr\|Q86UW0\|Q86UW0_HUMAN           Ovarian epithelial carcinoma-related protein OS=Homo sapiens PE=2 SV=1                                                                      8.757
  **8**    tr\|A0A024R2T8\|A0A024R2T8_HUMAN   Endonuclease G-like 1, isoform CRA_b OS=Homo sapiens GN=ENDOGL1 PE=4 SV=1                                                                   7.551
  **9**    tr\|D6RGG3\|D6RGG3_HUMAN           Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 PE=1 SV=1                                                                            6.66
  **10**   sp\|P25815\|S100P_HUMAN            Protein S100-P OS=Homo sapiens GN=S100P PE=1 SV=2                                                                                           5.38
  **11**   sp\|Q7L523\|RRAGA_HUMAN            Ras-related GTP-binding protein A OS=Homo sapiens GN=RRAGA PE=1 SV=1                                                                        4.567
  **12**   tr\|Q7Z3Y6\|Q7Z3Y6_HUMAN           Rearranged VH4-34 V gene segment (Fragment) OS=Homo sapiens GN=VH4-34 PE=4 SV=1                                                             4.433
  **13**   tr\|A0A0C4DH43\|A0A0C4DH43_HUMAN   Uncharacterized protein (Fragment) OS=Homo sapiens PE=4 SV=1                                                                                2.93
  **14**   tr\|Q9UL79\|Q9UL79_HUMAN           Myosin-reactive immunoglobulin light chain variable region (Fragment) OS=Homo sapiens PE=2 SV=1                                             2.865
  **15**   sp\|Q9UM07\|PADI4_HUMAN            Protein-arginine deiminase type-4 OS=Homo sapiens GN=PADI4 PE=1 SV=2                                                                        2.683
  **16**   tr\|B4E380\|B4E380_HUMAN           Histone H3 OS=Homo sapiens PE=2 SV=1                                                                                                        2.605
  **17**   tr\|D6RF35\|D6RF35_HUMAN           Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1                                                                                   2.355
  **18**   tr\|B1AH77\|B1AH77_HUMAN           Ras-related C3 botulinum toxin substrate 2 OS=Homo sapiens GN=RAC2 PE=1 SV=1                                                                2.195
  **19**   sp\|P62805\|H4_HUMAN               Histone H4 OS=Homo sapiens GN=HIST1H4L PE=2 SV=1                                                                                            2.172
  **20**   tr\|Q5NV63\|Q5NV63_HUMAN           V1-4 protein (Fragment) OS=Homo sapiens GN=V1-4 PE=4 SV=1                                                                                   2.092
  **21**   sp\|P68871\|HBB_HUMAN              Hemoglobin, beta OS=Homo sapiens GN=HBB PE=3 SV=1                                                                                           2.081
  **22**   tr\|D6R9C5\|D6R9C5_HUMAN           Osteopontin (Fragment) OS=Homo sapiens GN=SPP1 PE=1 SV=1                                                                                    2.078

COG annotation for all identified proteins {#s2_3}
------------------------------------------

All of the identified proteins were classified into different COG functional categories and subsequently into 23 subcategories (Figure [1](#F1){ref-type="fig"}). Most of these proteins were involved in "post-translational modification, protein turnover, chaperones" and in "general function prediction only".

![Histogram of the GOG Analysis\
x-axis displays the COG term, y-axis displays the corresponding protein count illustrating the protein number of different function.](oncotarget-10-2508-g001){#F1}

Pathway enrichment analysis of DEPs {#s2_4}
-----------------------------------

Data from Figure [1](#F1){ref-type="fig"} can be compared with the data in Figure [2](#F2){ref-type="fig"}, which shows that the P-value of retinol metabolism is the lowest in the B-VS-A pathway. The rich factor is the ratio of differentially expressed protein number annotated in this pathway to all proteins annotated in this pathway. A greater rich factor value corresponds to a greater intensiveness. The P-value ranges from 0\~1, and a lower P-value indicates greater intensiveness (Figure [2](#F2){ref-type="fig"}). The KEGG pathway of retinol metabolism is shown in Figure [3](#F3){ref-type="fig"}. Perisinusoidal stellate cells of the liver play important roles in retinol metabolism and fibrosis \[[@R6]\].

![**(A)**:class B vs class A; **(B):**class C vs class A; **(C):**class D vs class A; **(D):**class E vs class A Statistics of pathway enrichment of differentially expressed proteins in each pairwise. RichFactor is the ratio of differentially expressed protein number annotated in this pathway term to all protein number annotated in this pathway term. Greater richFator means greater intensiveness. Pvalue ranges from 0\~1, and less Pvalue means greater intensiveness.](oncotarget-10-2508-g002){#F2}

![The KEGG pathway of "retinol metabolism"\
Down-regulated proteins are marked with with green borders and non-change proteins are marked with black borders.](oncotarget-10-2508-g003){#F3}

There are 6 differentially expressed proteins annotated in retinol metabolism (Table [2](#T2){ref-type="table"}), which are alcohol dehydrogenase 1A; epididymis luminal protein 9; alcohol dehydrogenase IB (Class I), beta polypeptide, isoform CRA_a; alcohol dehydrogenase 6; aldehyde oxidase and alcohol dehydrogenase 4.

###### differentially expressed protein annotated in retinol metabolism

  ------------------------------------------------------------------------------------------------------------------------------
  No.     Protein_ID                 Description                                                            Ratio_B\_114/A_113
  ------- -------------------------- ---------------------------------------------------------------------- --------------------
  **1**   sp\|P00325\|ADH1B_HUMAN    Alcohol dehydrogenase IB (Class I), beta polypeptide, isoform CRA_a\   0.299
                                     OS=Homo sapiens GN=ADH1B PE=4 SV=1                                     

  **2**   sp\|P07327\|ADH1A_HUMAN    Alcohol dehydrogenase 1A OS=Homo sapiens GN=ADH1A PE=1 SV=2            0.399

  **3**   sp\|P08319\|ADH4_HUMAN     Alcohol dehydrogenase 4 OS=Homo sapiens GN=ADH4 PE=1 SV=5              0.438

  **4**   sp\|Q06278\|AOXA_HUMAN     Aldehyde oxidase OS=Homo sapiens GN=AOX1 PE=1 SV=2                     0.68

  **5**   sp\|P28332\|ADH6_HUMAN     Alcohol dehydrogenase 6 OS=Homo sapiens GN=ADH6 PE=1 SV=2              0.721

  **6**   tr\|V9HVX6\|V9HVX6_HUMAN   Epididymis luminal protein 9 OS=Homo sapiens GN=HEL-9 PE=2 SV=1        0.808
  ------------------------------------------------------------------------------------------------------------------------------

DISCUSSION {#s3}
==========

Quantification of the proteins via iTRAQ analysis has been suggested to be a suitable strategy for the identification of biomarkers since iTRAQ allows the comparison of protein abundance among samples by measuring the peak intensities of reporter ions released from the iTRAQ-tagged peptides. In this study, iTRAQ was combined with Gene Ontology (GO) and pathway analysis to identify the proteins that are differentially expressed in LT and determine their predicted functions.

Among the differentially expressed proteins in Table [1](#T1){ref-type="table"} and based on published studies, protein S100-P was found to be relevant to liver cancer. However, in the other groups, C-VS-A_up, D-VS-A_up and E-VS-A_up, S100-P was not significantly upregulated.

S100 calcium-binding protein P (S100P) is a protein that is encoded by the S100P gene in humans \[[@R7]\]. The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells and are involved in the regulation of a number of cellular processes, such as cell cycle progression and differentiation. S100 genes include at least 13 members that are located as a cluster on chromosome 1q21; however, this gene is located at 4p16. This protein, in addition to binding Ca2+, also binds Zn2+ and Mg2+. This protein may play a role in the aetiology of prostate cancer \[[@R8]\]. S100P regulates the calcium signal transduction pathway to mediate cytoskeletal interactions and is induced by the prostaglandin E2 (PGE2)/EP4) receptor signalling pathway in colon cancer cells \[[@R9]\]. The ectopic expression of S100P in SW 480 CRC promotes invasion and metastasis and decreases sensitivity to 5-FU *in vitro* \[[@R10]\]. The results of Hui Dong et al. indicated that S100P was upregulated in HCC, suggesting a possible role for S100P in liver cancer. The increased expression of both CCL20 and S100P genes was detected in HCC by quantitative RT-PCR, although they were found to be significantly upregulated in HepG2 but not in HCC SAGE data \[[@R11]\].

In this study, we found that the concentration of S100P in the serum before transplantation (class B) was 5.38x higher than that of the control group (class A). The GO biological processes associated with S100P were cellular process, localization, locomotion, response to stimulus and single-organism process. The GO cellular components associated with S100P were cell part and organelle. The GO molecular function associated with S100P was binding.

Aldehyde oxidase (AO) is a metabolizing enzyme and plays a very important role in the metabolization of numerous drugs. AO catalyses the oxidation of aldehydes into carboxylic acid and catalyses the hydrolysation of some heterocycles. In addition, AO can catalyse the oxidation of both cytochrome P450 (CYP450) and monoamine oxidase (MAO) intermediate products \[[@R12]\]. However, in the other groups, C-VS-A_up, D-VS-A_up and E-VS-A_up, S100-P was not significantly upregulated.

We found that the concentration of AO in the serum of patients before transplantation (class B) was 1.47x lower than that of the control group (class A). The GO biological process associated with AO were cellular process, metabolic process, and response to stimulus. The GO cellular component associated with AO was cell parts. The GO molecular function associated with AO were binding, catalytic activity, and electron carrier activity.

In conclusion, iTRAQ technology, which represents a relatively new strategy for proteomic analysis, was used here to study the changes in protein expression associated with liver cancer. This approach identified 2 significantly differentially expressed proteins (S100P and aldehyde oxidase) that were previously reported to be related to liver cancer. The MFs, CCs and BPs associated with these proteins indicate that they may be suitable liver biomarkers, which may improve the timeliness and accuracy of diagnosis. However, further investigation of the functions of these proteins, as well as of the proteins with high fold changes in liver cancer identified herein, is needed.

MATERIALS AND METHODS {#s4}
=====================

Samples. Serum samples were obtained from liver transplant patients between October 2014 and August 2015 at the Guilin 181^st^ Hospital (Guilin No. 181 Hospital officially changed its name to Guilin No. 924 Hospital), Guangxi, China. All patients were transplanted for HCC.

Serum samples were collected from 9 healthy volunteers who served as controls (class A) and from 9 liver transplant patients at different timepoints as follows: before transplantation (class B) and after transplantation on the 1st (class C), the 3rd (class D) and the 7th (class E) days. The main clinical and biochemical characteristics of liver transplant patients and the control group are shown in Table [3](#T3){ref-type="table"}.

###### Main clinical and biochemical characteristics of patients with liver transplant and the control group

                           class A    class B     class C      class D      class E
  ------------------------ ---------- ----------- ------------ ------------ -----------
  Peripheral samples (n)   9          9           9            9            9
  Ages (years)             44±12      47±15       47±15        47±15        47±15
  Sex(male/female)         8/1        8/1         8/1          8/1          8/1
  ALT (IU/L)               25.3±9.0   80.2±20.1   315.7±60.3   178.5±39.8   81.1±29.4
  AST(IU/L)                21.7±7.9   65.5±22.3   293.8±62.5   161.4±41.5   69.5±31.8

This study was performed according to the guidelines set forth by the Guilin 181st Hospital and abides by the Declaration of Helsinki on ethical principles for medical research involving human subjects. Written informed consent was obtained from all the subjects or their guardians.

Sample preparation {#s4_1}
------------------

Serum (5 ml) was collected from the enrolled subjects in a coagulation tube; the serum was separated, and 100 μl aliquots were stored at -80°C until further use.

iTRAQ {#s4_2}
-----

The concentration of the extracted protein was measured using the Bradford method. According to the concentration results, 30 μg of protein was removed from each sample for electrophoresis. Then, 100 μg of protein was accurately removed for digestion from each sample solution.

After trypsin digestion, the peptides were vacuum centrifuged to dryness. The iTRAQ labelling of peptide samples was performed using the iTRAQ Reagent 8-plex Kit according to the manufacturer\'s protocol. The peptides labelled with respective isobaric tags were incubated for 2 h. The iTRAQ-labelled peptides were fractionated using RP.

Peptide fractionation by RP chromatography {#s4_3}
------------------------------------------

For RP chromatography using the Shimadzu LC-20AB HPLC Pump System, the peptides from digestion were reconstituted with buffer A (5% acetonitrile, 95% H2O, adjusted to pH 9.8 with ammonia) to 2 ml and loaded onto a 4.6×250 mm Gemini C18 column containing 5 μm particles (Phenomenex). The peptides were eluted at a flow rate of 1 mL/min with a gradient of 5% buffer B (5% H2O, 95% acetonitrile, adjusted to pH 9.8 with ammonia) for 10 min, 5-35% buffer B for 40 min, and 35-95% buffer B for 1 min. The system was then maintained in 95% buffer B for 3 min and decreased to 5% within 1 min before equilibrating with 5% buffer B for 10 min. Elution was monitored by measuring absorbance at 214 nm, and fractions were collected every 1 min. The eluted peptides were pooled as 20 fractions and vacuum-dried.

LC-ESI-MS/MS analysis based on Triple TOF 5600 {#s4_4}
----------------------------------------------

Each fraction was resuspended in buffer A (5% acetonitrile, 0.1% FA) and centrifuged at 20,000 × g for 10 min, and the final concentration of peptide was approximately 0.5 mg/mL. The supernatant was loaded on a LC-20AD Nano HPLC (Shimadzu, Kyoto, Japan) by the autosampler onto a 2 cm C18 trap column. Then, the peptides were eluted into a 18 cm analytical C18 column (inner diameter 75 mm, packed in-house). The samples were loaded at 8 mL/min for 4 min, continued by a 41 min gradient running at 300 nL/min from 5 to 35% buffer B (95% acetonitrile, 0.1% FA), followed by a 5 min linear gradient to 80% buffer B; the samples were maintained at 80% for 5 min and finally returned to 5% for 1 min.

Bioinformatic pipeline {#s4_5}
----------------------

After the quantification of proteins, all the proteins with a false discovery rate (FDR) of less than 1% proceeded with the downstream analysis, including GO, COG and Pathway. Further, we performed deep analysis based on differentially expressed proteins, including Gene Ontology (GO) enrichment analysis, KEGG pathway enrichment analysis and cluster analysis.

The authors thank the patients and healthy volunteers who participated in the study and the members of staff for their assistance. This study was supported by the National Natural Science Foundation of China (Grant No. 81671596), the Science and Technology Planning Project of Guangdong Province, China (No. 2016A050503009), the Science and Technology Plan of Shenzhen (No. JCYJ20160422164313440), the Science and Technology Plan of Shenzhen (No. JCYJ20170307095606266), the Guangxi Natural Science Foundation (No. 2017GXNSFAA198185), the Guilin Research and Technology Development Project contract, the Scientific and Technological Innovation Ability and Condition Construction (No. 20170117-1), the National Natural Science Foundation of China (81670596) and the Guangxi Science and Technology Development Project (14124003-8).

**CONFLICTS OF INTEREST**

The authors have no conflicts of interest.
